Intravenous enzyme replacement therapy (ERT) with recombinant human iduronate-2-sulfatase (idursulfase; Takeda Pharmaceuticals USA, Inc., Lexington, MA, USA) is considered to be the current standard of care for MPS II [10, 11]. This evidence concerns the gene IDS and mucopolysaccharidosis type 2.